Search

Your search keyword '"Robson, Mark"' showing total 97 results

Search Constraints

Start Over You searched for: Author "Robson, Mark" Remove constraint Author: "Robson, Mark" Publisher elsevier bv Remove constraint Publisher: elsevier bv
97 results on '"Robson, Mark"'

Search Results

4. Development of a novel measure of advanced cancer patients’ perceived utility of secondary germline findings from tumor genomic profiling

5. “I don’t need any more unknowns hanging over my head”: Cancer patients’ views on variants of uncertain significance and low/moderate risk results from genomic sequencing

6. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

8. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer

11. P063: Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 individuals*

12. Metabolome-wide association study of the relationship between chlorpyrifos exposure and first trimester serum metabolite levels in pregnant Thai farmworkers

13. Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study

14. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

16. Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing

17. Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer

18. Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer

19. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

20. The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care

21. Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial

22. Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers

23. Early-onset renal cell carcinoma: assessment of germline genetic testing criteria

24. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma

25. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

28. Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations

29. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

30. Toward automation of germline variant curation in clinical cancer genetics

31. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology

32. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

34. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

35. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients

37. Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study

38. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes

39. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper

40. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

42. Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer

43. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

44. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

46. Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole

Catalog

Books, media, physical & digital resources